Last A$0.03 AUD
Change Today 0.00 / 0.00%
Volume 90.0K
PRR On Other Exchanges
As of 6:09 PM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (PRR) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/17/14 - A$0.07
52 Week Low
12/11/14 - A$0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PRIMA BIOMED LTD (PRR)

Related News

No related news articles were found.

prima biomed ltd (PRR) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (PRR) Details

Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product currently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.

31 Employees
Last Reported Date: 08/27/14

prima biomed ltd (PRR) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: A$250.2K
Chief Technical Officer
Total Annual Compensation: A$325.6K
General Counsel and Company Secretary
Total Annual Compensation: A$160.0K
Total Annual Compensation: A$364.4K
Compensation as of Fiscal Year 2014.

prima biomed ltd (PRR) Key Developments

Frédéric Triebel Joins Prima Biomed Ltd as its New Chief Scientific Officer and Chief Medical Officer

Prima BioMed Ltd. announced acquisition of Immutep SA has been completed. Prima also announced that Professor Frédéric Triebel has joined the company as its new Chief Scientific Officer and Chief Medical Officer. Professor Triebel originally developed Immutep's LAG-3 technology and was its founder and Scientific and Medical Director.

Prima BioMed Ltd Initiates Pancreatic Clinical Trial with CVac

Prima BioMed Ltd. announced that it has received the necessary regulatory approvals for the commencement of a single-arm, pilot trial for CVac in pancreatic cancer patients in remission, protocol number CAN-301. Prima has received regulatory allowance and ethical approval in Bulgaria, Poland and Germany. Clinical sites are currently being initiated, following which patient screening will commence. Up to 40 patients will be enrolled with the primary endpoint to evaluate the safety and tolerability of CVac in patients who are in remission with resected stage I or stage II adenocarcinoma of the pancreas, and as such looking at the maintenance treatment of these patients. The annual incidence of pancreatic cancer in the major markets (USA, Japan, UK, Germany, France, Italy and Spain) is approximately 99,000 per annum. Of those, about 20,000 per annum are suitable for surgical resection and approximately 80-95% of those who survive surgery may be expected to benefit from CVac treatment. It will be the first time that CVac will be applied to a larger homogenous group of patients in a cancer indication other than ovarian cancer. Pancreatic cancer is one of the most aggressive forms of cancer. For patients who present with pancreatic cancer early (stage I or II) surgery remains the most promising treatment to offer a potential cure. However, even then best 5-year survival rates are approximately 10%-20% with a median survival of 18-24 months following surgery. Current literature strongly supports immunotherapeutic approaches to treating pancreatic cancer in a maintenance setting after resection.

Immutep, S.A., Prima Biomed Ltd. - M&A Call

To discuss the company's recent acquisition of Immutep SA


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRR:AU A$0.03 AUD 0.00

PRR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRR.
View Industry Companies

Industry Analysis


Industry Average

Valuation PRR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.0x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at